AC
KYTX icon

AXQ Capital’s Kyverna Therapeutics KYTX Stock Holding History

AXQ Capital’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,375
Closed -$31.9K – 870
2025
Q2 		$31.9K Buy
+10,375
New +$25.7K 0.01% 546

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AXQ Capital's KYTX Position: Q3 2025 in Review

AXQ Capital sold out of Kyverna Therapeutics (KYTX) in Q3 2025, closing a stake of 10,375 shares — an estimated $31.9K sold.

AXQ Capital first reported a position in KYTX in Q2 2025 and held it in 1 quarter. The position peaked at $31.9K in Q2 2025. 75 funds tracked by Wall St. Rank hold KYTX as of Q3 2025.

  • AXQ Capital reported no remaining Kyverna Therapeutics position as of Q3 2025 after selling out during the quarter.
  • AXQ Capital sold 10,375 Kyverna Therapeutics shares in Q3 2025, an estimated $31.9K.
  • AXQ Capital first reported a position in Kyverna Therapeutics in Q2 2025 and held it in 1 quarter.
  • AXQ Capital's Kyverna Therapeutics position peaked at $31.9K in Q2 2025.
  • 75 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2025.

Based on AXQ Capital's 13F filing for Q3 2025, filed 10 Nov 2025.